As companies begin to make plans for 2025, add the INVEST Pitch Perfect Contest to your calendar. The post Are You a Startup Looking for an Audience of Investors? We Have The Perfect Pitch Contest for You! appeared first on MedCity News.
Hospitals started 2025 with a stable financial performance driven by strong patient volumes, but rising costs for drugs, supplies, and services continue to put major pressure on margins. The post How Are Hospitals Faring Financially in 2025? appeared first on MedCity News.
Ampreloxetine’s Phase 3 failure in multiple system atrophy is the third disappointing clinical trial outcome for the Theravance Biopharma drug. The biotech will now wind down all R&D and explore options that could include the sale of the company. The post Theravance Drug Fails Another Pivotal Test, This Time Sparking Restructuring That Ends R&D appeared…
Glycomine’s lead program is an experimental treatment for PMM2-CDG, an ultra-rare enzyme deficiency often misdiagnosed as cerebral palsy. With encouraging results from an open-label Phase 2 study, the biotech startup is now preparing for a placebo-controlled test that could potentially support a regulatory submission. The post Startup Glycomine Lands $115M for Clinical Trial in Ultra-Rare…
When the catastrophic Los Angeles fires broke out, John Volckens suspected firefighters and residents were breathing toxic air from the burning homes, buildings, and cars, but it was unclear how much risk the public faced. So, the professor of environmental health at Colorado State University devised a plan to get answers. Volckens shipped 10 air…
The label expansion for Boehringer Ingelheim’s Hernexeos was made under an FDA pilot program that accelerates regulatory review of products with national interest. The daily pill is now approved as a first-line treatment for HER2-positive non-small lung cancer, an indication with few treatment options. The post FDA Voucher Leads to Speedy Approval of Boehringer Drug…
We must continuously improve our education system, spanning from classroom to continued education, with vetted techniques that acknowledge the chaos and complexity of the healthcare environment. Learning by doing — our version of emergency weather drills — must happen before the storm hits, not during it. The post Why Nurse Competency Training Should Mirror Weather…
Alkermes is chasing Takeda Pharmaceutical, whose orexin receptor-targeting pill is on track to become first in a new class of narcolepsy medicines. Blair Jackson, chief operating officer of the neuroscience biotech, says Alkermes’s drug offers advantages and also paves the way to bring orexin agonism to other indications. The post Neuroscience Biotech Alkermes Sees Narcolepsy…
The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
Inaccurate provider data is creating a hidden crisis in healthcare by delaying care and driving up costs for both patients and health plans, according to CAQH CEO Sarah Ahmad. Her organization is working to address the issue by improving how provider data is collected and verified on the front end. The post Bad Provider Data…